Clinical Trial Update: Buspirone for Weak or Absent Esophageal Peristalsis [Phase 4]

View source ↗

Summary

A Phase 4 trial is evaluating buspirone for weak or absent esophageal peristalsis in patients with dysphagia. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dysphagia
• Esophageal Dysmotility

Drugs mentioned

• Buspirone (buspirone)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Dysphagia, Esophageal | Phase 4 | Status: RECRUITING